Cerevance Media Center
Current News
May 2, 2024
Cerevance Achieves First Milestone in Research Collaboration with Merck
Cerevance achieves first milestone in research collaboration with Merck, known as MSD outside of the United States and Canada. The research collaboration, which was announced in August of 2022, focuses on the identification of novel therapeutic targets for Alzheimer’s disease. The achievement of this milestone triggers an undisclosed payment from Merck to Cerevance.
April 25, 2024
Cerevance Adds $47 Million in Series B-1 Extension to Advance Robust Clinical Pipeline
Cerevance announced an initial closing of its Series B-1 Extension financing round that will add $47 million to the $51 million previously raised bringing the total Series B-1 raise to $98 million.
April 22, 2024
Cerevance Publishes CVN293 in ACS Medicinal Chemistry Letters
Cerevance announces that the peer-reviewed journal, ACS Medicinal Chemistry Letters, has published the manuscript titled “Discovery of CVN293, a Brain Permeable KCNK13 (THIK-1) Inhibitor Suitable for Clinical Assessment”.
February 15, 2024
Cerevance Announces Publication of CVN766 in Bioorganic & Medicinal Chemistry Letters
Cerevance Announces Publication of CVN766 in Bioorganic & Medicinal Chemistry Letters describing the discovery and initial development of CVN766 in the peer-reviewed journal, Bioorganic & Medicinal Chemistry Letters. In the publication titled, “Discovery and first-time disclosure of CVN766, an exquisitely selective orexin 1 receptor antagonist”
News Archive
May 9, 2024
Cerevance Presents at IAPRD XXIX World Congress on Parkinson’s Disease and Related Disorders
Cerevance will present an oral presentation at the upcoming International Association of Parkinsonism and Related Disorders (IAPRD) XXIX World Congress on Parkinson’s Disease and Related Disorders, taking place in Lisbon, Portugal from May 19-22, 2024. Karl Kieburtz, MD, MPH, will share Phase 2 study findings that enhance the confidence in CVN424's potential to address both motor and non-motor symptoms of Parkinson’s disease, consistent with observations in pre-clinical models, potentially heralding a transformative non-dopaminergic therapy.
April 29, 2024
Cerevance to Present at RBC Capital Markets 2024 Global Healthcare Conference
Cerevance company management to present at RBC Capital Markets 2024 Global Healthcare Conference, May 14-15, 2024. Craig Thompson, chief executive officer of Cerevance, will present a company overview on Wednesday, May 15, 2024, at 11:30 am ET. Cerevance management will also participate in one-on-one meetings with investors during the conference.
April 29, 2024
Cerevance to Participate at Wells Fargo Virtual Private Biotech Symposium
Cerevance company management to participate in upcoming Wells Fargo Virtual Private Biotech Symposium, May 6, 2024. Cerevance management will participate in one-on-one meetings with investors during the conference.
April 17, 2024
Cerevance Presents at 35th Symposium on Medicinal Chemistry in Eastern England
April 2, 2024
Cerevance to Participate at the 23rd Annual Needham Virtual Health Care Conference
March 13, 2024
Cerevance Announces Presentation at Alzheimer’s Research UK Conference
Events Archive
May 9, 2023
Uncovering Novel Cell Types and Therapeutic Targets in Alzheimer's Disease Using Cerevance’s NETSseq Platform and Analysis
March 31, 2023
NETSseq Reveals Deep Molecular Insights Into Alzheimer’s and Parkinson’s Disease and Facilitates Identification of Novel Therapeutic Targets
March 1, 2023